Download Zipped Amended WordPerfect HB0258.ZIP
[Introduced][Status][Bill Documents][Fiscal Note][Bills Directory]

H.B. 258

This document includes House Committee Amendments incorporated into the bill on Fri, Jan 25, 2008 at 3:37 PM by ddonat. -->              1     

MEDICAID DRUG UTILIZATION

             2     
AMENDMENTS

             3     
2008 GENERAL SESSION

             4     
STATE OF UTAH

             5     
Chief Sponsor: Rebecca D. Lockhart

             6     
Senate Sponsor: Curtis S. Bramble

             7     
             8      LONG TITLE
             9      General Description:
             10          This bill amends the Medical Assistance Act.
             11      Highlighted Provisions:
             12          This bill:
             13          .    prohibits the inclusion of immunosuppressive drugs used to prevent transplanted
             14      organ rejection from inclusion on:
             15              .     the preferred drug list for the State Medicaid Program;
             16              .    step therapy requirements of the Drug Utilization Board; and
             17              .    generic substitution requirements of the State Medicaid Program.
             18      Monies Appropriated in this Bill:
             19          None
             20      Other Special Clauses:
             21          None
             22      Utah Code Sections Affected:
             23      AMENDS:
             24          26-18-2.4, as last amended by Laws of Utah 2007, Chapter 385
             25     
             26      Be it enacted by the Legislature of the state of Utah:
             27          Section 1. Section 26-18-2.4 is amended to read:


             28           26-18-2.4. Medicaid drug program.
             29          (1) A Medicaid drug program developed by the department under Subsection 26-18-2.3
             30      (2)(f):
             31          (a) shall, notwithstanding Subsection 26-18-2.3 (1)(b), be based on clinical and
             32      cost-related factors which include medical necessity as determined by a provider in accordance
             33      with administrative rules established by the Drug Utilization Review Board;
             34          (b) may include therapeutic categories of drugs that may be exempted from the drug
             35      program;
             36          (c) may include placing some drugs, except [psychotropic or anti-psychotic drugs] the
             37      drugs described in Subsection (3), on a preferred drug list to the extent determined appropriate
             38      by the department; and
             39          (d) (i) except as prohibited by Subsections 58-17b-606 (4) and (5), shall permit a health
             40      care provider with prescriptive authority to override the restrictions of a preferred drug list
             41      provided that the medical necessity for the override is documented in the patient's medical file
             42      and by handwriting on the prescription "medically necessary - dispense as written"; and
             43          (ii) shall not permit a health care provider with prescriptive authority to override the
             44      restrictions of a preferred drug list with any preprinted instructions for dispense as written, or
             45      no substitutions allowed.
             46          (2) If the department implements a drug program under the provisions of Subsection
             47      (1)(c), the department shall:
             48          (a) determine the percentage of prescriptions that are paid for by the department which
             49      are overrides to the preferred drug list under Subsection (1)(d)(i);
             50          (b) include the information required by Subsection (2)(a) in the report required by
             51      Subsection (2)(c); and
             52          (c) report its findings regarding the drug program to the Legislative Health and Human
             53      Services Interim Committee by August 30, 2008, and to the Legislative Health and Human
             54      Services Appropriations Subcommittee during the 2009 General Session.
             55          (3) (a) For purposes of this Subsection (3), "immunosuppresssive drug":
             56          (i) means a drug that is used in immunosuppressive therapy to inhibit or prevent
             57      activity of the immune system to aid the body in preventing the rejection of transplanted organs
             58      and tissue; and


             59          (ii) does not include drugs used for the treatment of autoimmune disease or diseases
             60      that are most likely of autoimmune origin.
             61          (b) A preferred drug list developed under the provisions of this section may not
             62      include:
             63          (i) a psychotropic or anti-psychotic drug; or
             64          (ii) an immunosuppressive drug.
             65          (c) H. [ Notwithstanding the provisions of Subsection 58-17b-606 (4), the state Medicaid
             66      drug program may not require the substitution of a generic equivalent for an
             67      immunosuppressive drug without written or oral consent from the health care provider and the
             68      patient
] The state Medicaid program shall reimburse for a prescription for an
             68a      immunosuppressive drug as written by the health care provider for a patient who has
             68b      undergone an organ transplant. For purposes of Subsection 58-17b-606(4), and with respect to
             68c      patients who have undergone an organ transplant, the prescription for a particular
             68d      immunosuppressive drug as written by a health care provider meets the criteria of
             68e      demonstrating to the Department of Health a medical necessity for dispensing the prescribed
             68f      immunosupresssive drug .H .
             69          (d) Notwithstanding the requirements of Part 2, Drug Utilization Review Board, the
             70      state Medicaid drug program may not require the use of step therapy for immunosuppressive
             71      drugs without the written or oral consent of the health care provider and the patient.




Legislative Review Note
    as of 12-18-07 7:00 AM


Office of Legislative Research and General Counsel


[Bill Documents][Bills Directory]